Miromatrix
Eden Prairie, US · 1 known investors
Miromatrix develops fully biologic organs using decellularization and recellularization technology for transplant patients. The company focuses on engineering transplantable kidneys, livers, and liver support devices to address the critical shortage of donor organs.
Founders & leadership
JR
Jeff RossExecutive
RC
Robert CohenNamed on SEC filing
JA
Joseph AlexanderSecretary
Board
RE
Ronald EibensteinerBoard director
TF
Timothy FlynnBoard director
WS
Walter SembrowichBoard director
TJ
Timothy J. PawlentyBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$39.5M disclosed across 2 rounds · 2013–2017
▶$15.7MraisedJul 2018 · 55 investors · BiotechnologyRule 506(b)
▶$15.7MraisedJul 2018 · 55 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ronald EibensteinerDirector
- Mark WagnerDirector
- Paul BuckmanDirector
- Jeffrey RossExecutive Officer, Director
- John J. ErbDirector
- Brian NieburExecutive Officer
- Offering amount
- $15.7M
- Amount sold
- $15.7M
- First sale
- Oct 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$23.8MraisedNov 2015 · 124 investors · BiotechnologyRule 506(b)
▶$23.8MraisedNov 2015 · 124 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Timothy FlynnDirector
- Robert CohenExecutive Officer, Director, Promoter
- Joseph AlexanderExecutive Officer
- Jeff RossExecutive Officer
- Ronald EibensteinerDirector
- Walter SembrowichDirector
- Timothy J. PawlentyDirector
- Offering amount
- $25M
- Amount sold
- $23.8M
- Minimum investment
- $50K
- Finders' fees
- $171.3K
- Placement agents
- Van Clemens & Co., Inc., Terence J. Redmond, Woodrow L. Blevins, Mark D. Witmer, Blake Capital Partners, LLC, Valenti Synergy Consulting, LLC, Charlie Nickoloff
- First sale
- Oct 2013
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlap
Mirum Pharmaceuticals14 shared keywordsMirum Pharmaceuticals is a biopharmaceutical company that develops and delivers therapies for people living with rare diseases. It operates in the U.S. and Europe, engaging with healthcare professionals, patients, and payers within applicable regulatory frameworks.
Bioworld12 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Mereo BioPharma Group9 shared keywordsMereo BioPharma is a biopharmaceutical company publicly traded on Nasdaq under the ticker MREO. This page presents its share price data and SEC filings for investors and commercial partners.
Epirium9 shared keywordsEpirium Bio develops novel oral therapeutics targeting mitochondrial dysfunction and muscle diseases, particularly muscular dystrophy. The company's lead compound, EPM-01, is in Phase 1 clinical development for Becker muscular dystrophy.
Companies competing with Miromatrix for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Miromatrix do?
- Miromatrix develops fully biologic organs using decellularization and recellularization technology for transplant patients. The company focuses on engineering transplantable kidneys, livers, and liver support devices to address the critical shortage of donor organs.
- Who are Miromatrix's investors?
- Miromatrix's investors include Brightstone Venture Capital.
- How much funding has Miromatrix raised?
- Miromatrix has disclosed $39.5M raised across 2 rounds.
- Where is Miromatrix headquartered?
- Miromatrix is headquartered in Eden Prairie, US.